U
BIO icon

UBS’s Bio-Rad Laboratories Class A BIO Stock Holding History

UBS’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-200
Closed -$26K – 10415
2014
Q1 		$26K Buy
+200
New +$25.6K ﹤0.01% 7733

Other funds holding BIO

ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's BIO Position: Q3 2014 in Review

UBS reduced its Bio-Rad Laboratories Class A (BIO) stake by 29% in Q3 2014, selling an estimated $688K and leaving 14,336 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #3104.

UBS first reported a position in BIO in Q2 2013 and has held it in 6 quarters since. The position peaked at $3.29M in Q4 2013. 200 funds tracked by Wall St. Rank hold BIO as of Q3 2014.

  • UBS held 14,336 shares of Bio-Rad Laboratories Class A worth $1.63M as of Q3 2014.
  • UBS sold 5,804 Bio-Rad Laboratories Class A shares in Q3 2014, an estimated $688K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3104 holding.
  • UBS first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 6 quarters since.
  • UBS's Bio-Rad Laboratories Class A position peaked at $3.29M in Q4 2013.
  • 200 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.